Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 4Thoracic 2Gastrointestinal 2CNS 2Head & Neck 1Genitourinary 1Endocrine 1

Conditions

Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Pancreatic Neoplasms 1Melanoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1

Interventions

Nivolumab 2Bortezomib 2vatalanib 1tovorafenib 1tipifarnib 1spartalizumab 1sargramostim 1romidepsin 1pentetreotide 1pasireotide 1milademetan 1fludarabine phosphate 1entrectinib 1entinostat 1dabrafenib 1cobimetinib 1avelumab 1alectinib 1aldesleukin 1Vemurafenib 1Taxes 1Specimen Handling 1Rose Bengal 1Quality of Life 1Patient Reported Outcome Measures 1Paclitaxel 1PLX8394 1Molecular Diagnostic Techniques 1Microscopy, Electron 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × tovorafenib × Endocrine × Clear all
NCT04985604 2025-10-02

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Day One Biopharmaceuticals, Inc.

Phase 2 Terminated
23 enrolled 15 charts
CNSDermatologicEndocrineGastrointestinalGenitourinaryHead & NeckThoracic

Thyroid Cancer, Papillary, Astrocytoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡